Armata Pharmaceuticals, Inc. (ARMP) stock
ARMPNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.87+0.15 (+4.03%)
Close on Nov 13, 2026Market cap $143.89MP/E –Yield –
Armata Pharmaceuticals ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Armata Pharmaceuticals's ebitda for the twelve months ending Sep 30, 2025 was -$31.86M. For fiscal 2024 it was -$41.11M.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -$41.11M | – |
| FY2023 | Dec 31, 2023 | -$39.92M | – |
| FY2022 | Dec 31, 2022 | -$36.05M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2025 | Sep 30, 2025 | -$7.41M | – |
| Q2 FY2025 | Jun 30, 2025 | -$6.48M | – |
| Q1 FY2025 | Mar 31, 2025 | -$7.81M | – |
| Q4 FY2024 | Dec 31, 2024 | -$10.16M | – |
| Q3 FY2024 | Sep 30, 2024 | -$9.44M | – |
| Q2 FY2024 | Jun 30, 2024 | -$11.60M | – |
| Q1 FY2024 | Mar 31, 2024 | -$9.91M | – |
| Q4 FY2023 | Dec 31, 2023 | -$9.29M | – |
| Q3 FY2023 | Sep 30, 2023 | -$10.12M | – |
| Q2 FY2023 | Jun 30, 2023 | -$9.40M | – |
| Q1 FY2023 | Mar 31, 2023 | -$11.12M | – |
See a number that looks wrong?